SectorBiological Technology
Established Date26/09/2012
Listing Date21/12/2012
ExchangeNASDAQ Stock Exchange
Full-time Employees67
Fiscal Year Ends31/12
Security TypeCommon stock
Office address77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland
Business
IntroductionProthena Corporation plc was incorporated under the laws of Ireland on 26 September 2012 and re-registered as an Irish public limited company on 25 October 2012. The company is a late-stage clinical biotechnology company with expertise in protein disorders and a range of investigational therapies that have the potential to alter the course of disruptive neurodegenerative diseases and rare peripheral amyloid diseases. The company's wholly-owned projects include birtamimab for the potential treatment of AL amyloidosis, and a series of projects for the potential treatment of Alzheimer's disease, including PRX012 for β-amyloid (Aβ) and the new Aβ-tau dual vaccine PRX123.
